研究单位：[1]Sichuan Cancer Hospital and Research Institute[2]Innovent Biologics,Inc.
研究目的：
The aim of this study was to investigate the safety and efficacy of Sintilimab (IBI308) in patients with resectable NSCLC,and to provide new treatment options for neoadjuvant therapy in patients with stage II-IIIA NSCLC
